Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature

详细信息    查看全文

• 作者：Michalina Kołodziejczak^a ; ^b ; Eliano P. Navarese^a ; ^c ; ^{elianonavarese@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Mortality ; Neurocognitive effects ; PCSK9 antibodies ; Meta-analysis
• 刊名：Atherosclerosis
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：247
• 期：Complete
• 页码：189-192
• 全文大小：454 K

文摘

Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) are a novel lipid-lowering approach found to improve clinical outcomes in patients with dyslipidemia. With coronary artery disease remaining the most frequent cause of morbidity and mortality worldwide, a drug offering a true mortality reduction should be appropriately regarded as a novel blockbuster in cardiovascular medicine, provided that significant side effects do not emerge. However, a recent study may suggest an increase of neurocognitive adverse events with those drugs. A critical overview of current evidence on neurocognitive outcomes as well as the meta-analytical approach with open-label extension trials evaluating PCSK9 monoclonal antibodies is needed to avoid potential controversy.